Quality of Care for Knee and Hip Osteoarthritis in Elderly Patients (QSAMISA)

November 19, 2019 updated by: Assistance Publique - Hôpitaux de Paris

Quality of Care for Knee and Hip Osteoarthritis in Elderly Patients: a Multicentric Observational Study in France Using Quality Indicators Assessed by Questionnaire

Introduction: Hip and knee osteoarthritis (OA) was ranked in 2010 as the eleventh highest contributor to global disability. In France in 2014, non-spinal OA was the leading self-reported cause of morbidity among adults over sixty-five years of age, with a prevalence of 49.5 per cent. OA is known to be the first cause of disability in activities of daily life and a risk factor of frailty among people over seventy-five years of age. Despite its major impact on the elderly population's quality of life and health, quality of care for OA in elderly patients remains understudied.

Objective: The study aims to assess the quality of care for knee and hip OA in patients aged 75 years and over.

Study Overview

Detailed Description

Method: This prospective multicentric observational cohort study enrolls participants of 75 years and over with symptomatic hip or knee OA for more than three months, hospitalized in seven geriatric departments of three hospitals of "Assistance Publique - Hôpitaux de Paris", for any cause of admission. Quality of care for OA before hospitalization is assessed by the Assessing Care of Vulnerable Elderly's (ACOVE) quality indicators (QI) for OA, using a questionnaire. The primary endpoint is the pass rate for the ACOVE's QI about referral to an orthopedic surgeon for patients with severe functionally compromising knee or hip OA. The secondary endpoints are the pass rates for the six others ACOVE's QI for OA (annual assessment of functional status and degree of pain ; exercise therapy for patients with newly diagnosed knee OA ; education regarding the natural history, treatment, and self- management of OA ; acetaminophen as first-line pharmacologic therapy ; advising patients treated with non-steroidal anti-inflammatory drugs (NSAIDs) of their risks ; offering prophylaxis with a proton-pump inhibitor or misoprostol to patients treated with non-selective NSAIDs) and other elements of hip or knee OA care not assessed by the seven QI (including use of opioid analgesics, NSAIDs, intra-articular infiltrations, joint replacements). The sample is described with a rheumatologic assessment including Western Ontario and MACmaster universities osteoarthritis index (WOMAC) and Kellgren-Laurence classification, and with a geriatric assessment including nutritional status, Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL) scores, Mini Mental State Examination (MMSE) score, Timed Up and Go walking test, modified Short Emergency Geriatric Assessment (mSEGA) scale and Cumulative Illness Rating Scale for Geriatrics (CIRS-G). Participants also complete the 12-Item Short Form Survey version 2 (SF-12v2) quality of life questionnaire. They receive a call twelve months after inclusion to collect vital status, orthopedic consultation and joint replacement during the last year.

Study Type

Observational

Enrollment (Anticipated)

405

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Créteil, France, 94010
        • Assistance Publique Hôpitaux de Paris - CHU Henri Mondor

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

75 years and older (Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients hospitalized in seven geriatric departments of three hospitals of "Assistance Publique - Hôpitaux de Paris", for any cause of admission

Description

Inclusion Criteria:

  • patients aged seventy-five years or over
  • with symptomatic hip or knee osteoarthritis according to the American College of Rheumatology criteria
  • with pain for more than three months
  • affiliated to French social security
  • having given their oral non-opposition to participate (or oral non-opposition of the guardian in case of legal guardianship)

Exclusion Criteria:

  • clinical or radiological sign suggesting a differential diagnosis for hip or knee pain
  • acute disease with clinical repercussion on walking
  • life-threatened patients

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
number of participants referred to an orthopedic surgeon as assessed by ACOVE's quality indicator questionnaire
Time Frame: at enrollment
at enrollment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
rate of eligible patients who passed the quality indicator about annual assessment of functional status and degree of pain, assessed by questionnaire
Time Frame: at enrollment
The eligibility criterion is answer "yes" to the question "Do you have pain in your joints that bothers you a lot on most days?". The pass criterion is a "yes" response to either of the two questions "In the past 12 months, has any doctor or nurse asked you about the severity of your joint pain?" "In the past 12 months, has any doctor or nurse asked you if your joint pain affects the things you like or need to do?". The rate is calculated using the numerator as the number of eligible patients who passed the quality indicator and the denominator as the number of patients eligible for the quality indicator.
at enrollment
rate of eligible patients who passed the quality indicator about exercise therapy for patients with newly diagnosed knee osteoarthritis, assessed by questionnaire
Time Frame: at enrollment
The eligibility criteria are knee pain that had lasted at least 3 months, health did not limit the patient's ability to bathe or dress, and patients or surrogates indicated that the patient did not have severe dementia. The pass criterion is a "yes" response to the question "Have you ever been sent to physical therapy or an exercise group or class for your knee pain?". The rate is calculated using the numerator as the number of eligible patients who passed the quality indicator and the denominator as the number of patients eligible for the quality indicator
at enrollment
rate of eligible patients who passed the quality indicator about education regarding the natural history, treatment, and self- management of osteoarthritis, assessed by questionnaire
Time Frame: at enrollment
The eligibility criterion is pain in any joint lasting at least 6 months. The pass criterion is a a "yes" response to at least 1 of the 3 questions "Has any doctor or nurse ever talked to you about what your arthritis or joint pain will be like as time goes on, or the natural history of arthritis?" "Has any doctor or nurse ever talked to you about how to keep your arthritis or joint pain from getting worse?" "Has any doctor or nurse ever talked to you about how your arthritis can be treated?". The rate is calculated using the numerator as the number of eligible patients who passed the quality indicator and the denominator as the number of patients eligible for the quality indicator.
at enrollment
rate of eligible patients who passed the quality indicator about acetaminophen as first-line pharmacologic therapy, assessed by questionnaire
Time Frame: at enrollment
The eligibility criterion is a "yes" response to the question "Has any doctor or nurse recommended any treatments for your joint pain?". The pass criterion is a "yes" response to the question "Did any doctor or nurse recommend you try acetaminophen before other medications for your joint pain?". Trade names of acetaminophen are mentioned to help participants. The rate is calculated using the numerator as the number of eligible patients who passed the quality indicator and the denominator as the number of patients eligible for the quality indicator.
at enrollment
rate of eligible patients who passed the quality indicator about advising patients treated with non-steroidal anti-inflammatory drugs (NSAIDs) of their risks, assessed by questionnaire
Time Frame: at enrollment
The eligibility criteria are NSAID on medication list, or a "yes" response to the question "Do you take any medications like aceclofenac, celecoxib, diclofenac, etoricoxib, ibuprofene, indometacine, ketoprofene, naproxene or piroxicam ? These medications are known as non-steroidal anti-inflammatory drugs". Corresponding trade names are mentioned to help participants. The pass criterion is a "yes" response to the question "Did any doctor or nurse or pharmacist tell you about the possible side effects or risks from taking this medication?". The rate is calculated using the numerator as the number of eligible patients who passed the quality indicator and the denominator as the number of patients eligible for the quality indicator.
at enrollment
rate of eligible patients who passed the quality indicator about offering prophylaxis with a proton-pump inhibitor or misoprostol to patients treated with non-selective NSAIDs, assessed by questionnaire
Time Frame: at enrollment
The eligibility criteria are NSAID on medication list, or a "yes" response to the question "Do you take any medications like aceclofenac, diclofenac, ibuprofene, indometacine, ketoprofene, naproxene or piroxicam?". Corresponding trade names are mentioned to help participants. The pass criterion is a "yes" response to the question "Did any doctor or nurse recommend you take another medication to protect your stomach or intestines or from developing an ulcer? For example omeprazole, esomeprazole, pantoprazole, lansoprazole or misoprostol". Corresponding trade names are mentioned to help participants. The rate is calculated using the numerator as the number of eligible patients who passed the quality indicator and the denominator as the number of patients eligible for the quality indicator.
at enrollment
percentage of patients taking non-steroidal anti-inflammatory drugs for their hip or knee osteoarthritis, assessed by questionnaire and reading current medical prescription
Time Frame: at enrollment
at enrollment
percentage of patients taking opioid analgesics for their hip or knee osteoarthritis, assessed by reading current medical prescription
Time Frame: at enrollment
at enrollment
percentage of patients taking symptomatic slow-acting anti-arthritics, assessed by assessed by reading current medical prescription
Time Frame: at enrollment
at enrollment
percentage of patients taking non-steroidal anti-inflammatory topically applied, assessed by assessed by reading current medical prescription
Time Frame: at enrollment
at enrollment
percentage of patients treated with intra-articular infiltration of corticosteroid, assessed by questionnaire
Time Frame: at enrollment
at enrollment
percentage of patients treated with intra-articular infiltration of visco-supplementation, assessed by questionnaire
Time Frame: at enrollment
at enrollment
percentage of patients who consulted a rheumatologist for their knee or hip osteoarthritis, assessed by questionnaire
Time Frame: at enrollment
at enrollment
percentage of patients who beneficiate from a modification of their medical prescription related to their knee or hip osteoarthritis treatment during or after their stay in the inclusion geriatric department, assessed by reading the medical record
Time Frame: after the patient discharge
after the patient discharge
percentage of patients referred to an orthopedic surgeon during or after their stay in the inclusion geriatric department, assessed by reading the medical record
Time Frame: after the patient discharge
after the patient discharge
percentage of patients referred to an orthopedic surgeon who really consulted the orthopedic surgeon, assessed by calling the patient one year after inclusion
Time Frame: one year after inclusion
one year after inclusion
percentage of patients referred to an orthopedic surgeon who beneficiated from a joint replacement for their hip or knee, assessed by calling the patient one year after inclusion
Time Frame: one year after inclusion
one year after inclusion
vital status at one year
Time Frame: one year after inclusion
one year after inclusion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Jean-Philippe David, PhD

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

December 1, 2019

Primary Completion (Anticipated)

December 1, 2021

Study Completion (Anticipated)

December 1, 2022

Study Registration Dates

First Submitted

October 25, 2019

First Submitted That Met QC Criteria

November 19, 2019

First Posted (Actual)

November 20, 2019

Study Record Updates

Last Update Posted (Actual)

November 20, 2019

Last Update Submitted That Met QC Criteria

November 19, 2019

Last Verified

October 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

DATAS ARE OWN BY ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, PLEASE CONTACT SPONSOR FOR FURTHER INFORMATION

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Knee Osteoarthritis

3
Subscribe